EP0422049A1 - Vektor zum abscheiden von proteinen direkt in das periplasma oder in das kulturmedium - Google Patents

Vektor zum abscheiden von proteinen direkt in das periplasma oder in das kulturmedium

Info

Publication number
EP0422049A1
EP0422049A1 EP89906964A EP89906964A EP0422049A1 EP 0422049 A1 EP0422049 A1 EP 0422049A1 EP 89906964 A EP89906964 A EP 89906964A EP 89906964 A EP89906964 A EP 89906964A EP 0422049 A1 EP0422049 A1 EP 0422049A1
Authority
EP
European Patent Office
Prior art keywords
gene
protein
pseudomonas exotoxin
domain
periplasm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP89906964A
Other languages
English (en)
French (fr)
Other versions
EP0422049A4 (en
Inventor
Ira Pastan
Sankar Adhya
David Fitzgerald
Vijay Chaudhary
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
US Department of Commerce
Original Assignee
US Department of Health and Human Services
US Department of Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, US Department of Commerce filed Critical US Department of Health and Human Services
Publication of EP0422049A1 publication Critical patent/EP0422049A1/de
Publication of EP0422049A4 publication Critical patent/EP0422049A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/495Transforming growth factor [TGF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/55Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/61Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)

Definitions

  • the invention relates generally to recombinant plasmids for expressing proteins that are secreted into periplasm or culture medium. More particularly, the invention relates to the construction of plasmids which, when introduced into an expression vector secrete proteins directly into the periplasm or extracellular culture medium in which the vectors are grown.
  • Proteins that are secreted into the periplasm of E. coli or inserted into E. coli membranes have several unique features. Nearly all proteins destined to be exported have a signal sequence (SS) which has been shown to be important for translocation. In addition, membrane or secreted proteins have structural features within the molecules that facilitate secretion or membrane insertion.
  • SS signal sequence
  • membrane or secreted proteins have structural features within the molecules that facilitate secretion or membrane insertion.
  • the construction of chimeric proteins have been studied in which portions of the Pseudomonas exotoxin (PE) gene are fused to other functional peptides and which are directed by the toxin to receptors on target cells. The chimeric genes are expressed in E. coli and the chimeric proteins are purified from the bacterial cells.
  • PE Pseudomonas exotoxin
  • X-ray crystallography of mature Pseudomonas exotoxin has shown that the molecule is composed of three distinct structural domains. Various portions of the Pseudomonas exotoxin gene have been deleted and expressed in E. coli in order to analyze the function of these domains. Study of the expressed mutant proteins has shown that the amino terminal domain I having amino acids 1 through 252, is responsible for receptor binding, the middle domain II having amino acids 253 through 384, is responsible for translocation of the toxin across membranes, and the carboxyl terminal domain III, having amino acids 385 through 384, contains the ADP-ribosylating activity.
  • Pseudomonas exotoxin is secreted by Pseudomonas aeruginosa into its growth medium.
  • the gene of this article is not related to a gene from a Pseudomonas exotoxin.
  • the industry is lacking an expression vector or plasmid having a Pseudomonas exotoxin that, when introduced into an appropriate host, causes a desired protein to secrete into the periplasm and/or the culture medium of the host cell in which the vector is grown.
  • the industry is also lacking a biological method for synthesizing pure or fusion proteins in large or commercially acceptable amounts which uses an expression vector or plasmid having Pseudomonas exotoxin.
  • the invention includes an expression vector that expresses a protein that secretes from a host cell into the periplasmic space and/or a medium of the host cell.
  • the expression vector comprises a gene portion or polypeptide segment for expressing at least amino acids 381 through 407 of Pseudomonas exotoxin and a gene for expressing the protein that is to be secreted from the host cell.
  • the gene is ligated near or to the first gene or to a gene providing a cleavage site between the protein and the Pseudomonas exotoxin amino acids.
  • the expression vector can include a signal sequence.
  • the invention includes the method for synthesizing pure protein from a host cell having an expression vector containing a gene for the desired protein and a gene portion for expressing at least a portion of domain II of Pseudomonas exotoxin.
  • the invention includes the expressed and secreted fusion or pure protein products of the invented process.
  • Figure 1 represents various Pseudomonas exotoxin derivatives and fusion proteins.
  • Figure 2 represents cellular localization of Pseudomonas exotoxin derivatives by immunoblotting.
  • a plasmid comprising a promoter, optionally, any outer membrane signal sequence attached to a gene for a protein which is desired to be secreted, and a PE40 gene required for translocating across membrane.
  • polypeptide segment in reference to domain II of Pseudomonas exotoxin refers to any consecutive group of amino acids from this exotoxin that increases the secretion of a protein to which it is fused.
  • Such polypeptide segments can include all of domain II of the Pseudomanas exotoxin.
  • polypeptide segments can include a portion of domain I and/or III of this exotoxin along with a functional portion of domain II.
  • gene portion refers to a segment or nucleotide sequence that encodes a polypeptide segment of domain II of the Pseudomonas exotoxin that increases the secretion of a protein to which the polypeptide segment is fused.
  • the desired protein to be secreted is referred to as the "selected protein.” Molecules containing domain II of Pseudomonas exotoxin are secreted into the periplasm of E. coli and under certain conditions are also secreted into the medium.
  • PE40 A molecule termed "PE40" which contains both domains II and III of Pseudomonas exotoxin is secreted into the periplasm without an OmpA signal sequence present and into the medium when the signal sequence is added. This result suggests that sequences within domain II in concert with a signal sequence can promote secretion of a protein into the medium. However, the deletion of all of domain I of Pseudomonas exotoxin and a portion of domain II also generates molecules that are secreted into the medium and periplasm without a signal sequence. In addition, the placement of alkaline phosphatase at the carboxyl terminus of a toxin molecule containing domain II alone or domains II and III also leads to secretion into the medium.
  • Domain II contains a large number of hydrophobic amino acids.
  • the amino terminus of each of the recombinant Pseudomonas exotoxin proteins can be constructed to contain the sequence met-ala-glu-glu. This amino terminus in the invented constructs is different from a conventional leader sequence which must possess positively charged amino acids in the amino terminal region. It has been reported that introduction of some random sequences in place of a signal sequence could lead to the secretion of invertase in yeast, but the results of the invention suggest that sequence within domain II of Pseudomonas exotoxin are important for secretion of molecules across E. coli membranes.
  • domain II When domain II is combined with a signal sequence such as that found in OmpA or with a protein which itself can be transported across a membrane such as alkaline phosphatase, secretion into the periplasm and into the medium results. Furthermore, a protein such a TGF-alpha can be efficiently transported into the medium or periplasm when fused to domains II and III of Pseudomonas exotoxin.
  • Domain II is composed of a series of alpha helices. Stretches of hydrophobic amino acids are present in these helices. Domain II is also required for efficient translocation of Pseudomonas exotoxin into the cytoplasm of animal cells during endocytosis.
  • Domain II of Pseudomonas exotoxin has an essential role in the secretion of the toxin into the periplasm and medium. Domain II can also promote the secretion of other molecules fused to it. Domain II has been examined by expressing modified Pseudomonas exotoxin genes in E. coli under to control of a T7 promoter. Without a signal sequence, Pseudomonas exotoxin accumulates within the cell, but it is secreted into the periplasm when part or all of domain I is removed.
  • Pseudomonas exotoxin appears in the periplasm and medium when domains I and part of II are removed. Domain II alone is secreted into the periplasm, whereas domain III alone remains within the cell. The addition of an ompA signal sequence results in the secretion of mature Pseudomonas exotoxin into the periplasm and secretion of domain II-III into the medium.
  • a protein composed of a transforming growth factor alpha, fused to the amino end of domain II-III, is secreted into the periplasm without a signal sequence and into the medium with a signal sequence.
  • a protein composed of domain II or II-III fused to the amino end of alkaline phosphatase is secreted into the periplasm and the medium with or without a signal sequence.
  • the preferred embodiment of the invention uses Pseudomonas exotoxin in an E. coli system, although expression vectors other than E. coli can also be used. A portion of the Pseudomonas exotoxin gene is fused to the gene of interest.
  • the protein is expressed in E. coli using a T7 late promoter expression system and an E. coli outer membrane protein signal sequence such as that of ompA, the chimeric protein is secreted into the medium in large amounts. If ompA signal sequence is not present, the chimeric protein is secreted into the periplasmic space.
  • Table 1 The results produced by ligations of various combinations of these elements are shown in Table 1.
  • T7 promoter/ompA/protein x /PE40 Medium T7 promoter/ompA/PE40/protein x Medium T7 promoter/PE40/protein x Periplasm T7 promoter/ompA/protein x Cytoplasm or Periplasma T7 promoter/protein x Cytoplasm
  • PE Pseudomonas exotoxin
  • the PE40 protein secreted into the medium has full biological activity and has a native structure. Usually foreign proteins made in E. coli accumulate in an aggregated form and must be denatured and renatured to yield an active protein, and then must be purified free of other E. coli proteins.
  • PE40 is secreted into the medium in an enriched and native form. Transport of fusion protein into periplasm can occur as follows. A cDNA for the transforming growth factor alpha (TGF-alpha) has been fused to the gene encoding PE40. The TGF-alpha gene has been placed at the 5' or the 3' end of the gene encoding PE40.
  • TGF-alpha transforming growth factor alpha
  • TGF-alpha-PE40 When placed at the 5' end (pXY 382) a fusion protein, TGF-alpha-PE40, is produced and some of it is transported into the periplasm.
  • a cDNA for the interleukin 2 gene can also be placed at the 5' end of PE40 (pHL 310) and it too is transported into the periplasm.
  • TGF-alpha fused at the 3' end of PE40 (coded by pVC33) is also transported into the periplasm, but the protein is degraded. Degradation of this protein may in part be due to the amino acids used to link PE40 to TGF-alpha.
  • Excretion of a fusion protein into the medium occurs as follows.
  • the gene encoding the TGF-alpha-PE40 fusion protein also contains an ompA signal sequence at its 5' end, the resulting protein is secreted into the medium in large amounts . More than 30% of the protein produced is found in the medium in an active form with 20% transported to periplasm.
  • Fusion genes in which genes encoding other proteins are fused to the coding sequence for Domain II alone or to Domains II and III or Pseudomonas exotoxin with a signal sequence are similarly constructed. Such genes are, for example, interleukin-2 and alkaline phosphatase.
  • Any gene encoding a protein that is usually transported across membranes of cells can also be secreted into the medium in accordance with the methodology of the present invention.
  • Numerous other genes for expressing and secreting desired proteins can be selected for use with the invention.
  • Such other selected proteins can include Staphylococcal nuclease, gal repressor, bacterial Cytoplasmic, Cyclic AMP receptor protein, bacterial Adenylate Cyclase and human soluble T40 receptor (CD4).
  • Pure proteins can be made from fused proteins produced by fusion genes by providing a site into the fusion protein that can be cleaved by a specific protease or a specific chemical reaction.
  • An example of such a site is cleavage by the enzyme collagenase. Collagenase splits at gly-leu or ile-ala-gly bonds which are found in collagen, but are rare in other proteins. Elastase is another such agent.
  • the candidate fusion protein does not contain an internal methionine residue, a codon for methionine can be created in between the candidate protein and the Pseudomonas exotoxin domains and cyanogen bromide can be used to generate the desired protein. Similar other strategies well known to one of ordinary skill in the art can also be used. Deposits have been made at the ATCC, Rockville, Maryland, on September 19, 1986, under the following accession numbers:
  • the deposits shall be viably maintained or replaced if they become non-viable, for a period of 30 years from the date of the deposit, or for 5 years from the last date of request for a sample of the deposit, whichever is longer, and made available to the public without restriction in accordance with the provisions of the law.
  • the Commissioner of Patents and Trademarks, upon request, shall have access to the deposit.
  • pVC4 was cut with Hindlll and Tth111l, treated with SI nuclease and the large fragment ligated to itself.
  • pVC20 pVC4 was cut with Hind III, treated with Klenow fragments of DNA polymerase I, and cut with Pstl to yield a 1.6 kb fragment.
  • pVC4 was cut with Bglll, treated with SI nuclease and then with Pstl. A 2.1 kb fragment was isolated and ligated to the 1.6 kb fragment to produce pVC20.
  • pVC85 pVC8 was treated sequentially with Ndel, S1 nuclease and Xbal and 3.6 kb fragment isolated.
  • pINIII OmpA1 was treated sequentially with EcoR1, Klenow fragment and Xbal and 92 bp fragment, carrying an ompA Shine-Dalgarno ( SD ) region and an ompA signal sequence was isolated.
  • the 3.6 kb fragment and the 92 bp fragment were ligated to produce pVC85.
  • Other plasmids with OmpA signal sequences were created similarly.
  • the phoA containing plasmids were constructed using a Pstl insert that contains the phoA gene.
  • pVC229 was constructed by treating pVC8 with Sst II followed by T4 DNA polymerase to yield a 3.65 kb fragment that was dephosphorylated.
  • pCH39 was treated with Pstl and T4 polymerase.
  • a 3 kb fragment was isolated, ligated to the 3.65 kb fragment and the recombinants were screened for proper orientation.
  • pVC2295 was constructed from pVC85 similarly.
  • pVC809 was constructed by treating pVC8 with PpuMI followed by Klenow fragment to yield a 3.65 kb fragment.
  • pCH2 was treated with Pstl and T4 polymerase to produce a 3.0 kb fragment. The two fragments were joined and recombinants checked for proper PhoA orientation.
  • pVC8095 was made from pVC85 similarly. Construction of pXY382 and pXY3825 is described below. These contain a TGF-alpha cDNA fused to the 5' end of the DNA for domains II and III of PE. pXY3825 also carries on ompA signal sequence. In all the plasmids, the genes are linked to a phage T7 late promoter. Other plasmids and bacterial strains were previously described. Plasmid construction is further understood with reference to Figure 1. Figure 1 is a representation of various Pseudomonas exotoxin derivatives and fusion proteins.
  • Plasmid pXY382 contains a TGF-alpha cDNA fused to the 5' end of domains II and III of Pseudomonas exotoxin.
  • the circled number "50" is the last amino acid of TGF-alpha.
  • pVC229 and 809 contain the phoA gene fused to the 3' end of the gene for domains II or II and III.
  • the plain numbers indicate Pseudomonas exotoxin amino acids.
  • the boxed number (6, 14) indicate PhoA amino acids. Gly and ala were added during cloning.
  • pVC2295 and pVC8095 are similar to pVC229 and pVC809 except for an ompA signal sequence.
  • E. coli BL21 (lambda DE3) cells carrying a desiredplasmid were grown and induced with IPTG and described above. After induction, the culture of 30 ml was centrifuged at 3000 rpm for 10 minutes. To obtain periplasmic and spheroplast fractions, the cell pellet was suspended in 1.5 ml sucrose solution of 20% sucrose w/w, 30 mM Tris, pH 7.4, 1 mM EDTA, kept on ice for 10 minutes and aliquots were removed for assay. The remainder was centrifuged at 6000 rpm and the supernatant of sucrose wash discarded.
  • Examples 1 through 8 and Comparative Examples A and B illustrate the localization of Pseudomonas exotoxin molecules with various portions delated.
  • Comparative Example A pVC4 encodes the entire Pseudomonas exotoxin protein with a methionine placed before the alanine at position 1. It was previously found that when the Pseudomonas exotoxin gene is expressed in E. coli, the toxin accumulates within the cell. Table I shows that over 98% of this molecule is found associated with spheroplasts. Proteins with deletions of progressive amounts of domain I encoded by pVC15, 19 and 20 were mostly found associated with spheroplasts but significant amounts appeared in the periplasm.
  • Example 4 using pVC8 98% of the Pseudomonas exotoxin synthesized was secreted into the periplasm. This is further illustrated in Figure 2A.
  • the protein produced by pVC8 has a Mr of 40,000 and hence is referred to as PE40. Deletion of increasing portions of domain II as in pVC9, 10 and 17, caused about 9% of the protein to appear in the medium with rest mostly appearing in the periplasm.
  • Comparative Example B using pVC7 the resulting protein which consists only of domain III remained within the cell.
  • pVC17 only contains 27 amino acids that are not present in pVC7 of Comparative Example B. These amino acids are very important for secretion.
  • Examples 9 through 13 illustrate the effect of the ompA signal sequence on secretion.
  • Signal sequences present in proteins of gram negative bacteria have been found to promote secretion of proteins into the periplasmic space or insertion of proteins into cell membranes.
  • the effect of an ompA signal sequence on the cellular distribution of various molecules derived from Pseudomonas exotoxin is, therefore, presented.
  • Table III shows that the ompA signal sequence present in Example 9 using pVC45 promotes the secretion of full length Pseudomonas exotoxin into the periplasm, but not into the medium.
  • a similar result was recently reported by Douglas et al. (1987), J. Bacteriol 169:4962-4966.
  • the ompA signal sequence apparently overcomes the inhibitory action of domain 1.
  • the OmpA signal sequence had very little effect on the secretion of molecules in which various portions of domain I were deleted and are already secreted into the periplasm. For example, pVC155 and pVC205 with deletion of amino acids 4-137 or 5-224, respectively.
  • the OmpA signal sequence did cause secretion into the medium of a molecule containing only domains II and III. This is further illustrated in Figure 2B. Addition of an ompA signal sequence also resulted in the secretion into the medium of domain II by itself as shown in Figure 2E.
  • an ompA signal sequence precedes a protein composed of domain II alone or of domain II and III, the protein is secreted into the medium.
  • the Pseudomonas exotoxin molecules present in the periplasm and in the medium are slightly smaller than the molecules in the spheroplasts indicating removal of the signal sequence as shown in Figure 2B and E.
  • Purified PE40 from the medium of cells producing it has the N-terminal sequence of ala-asn-leu-ala. This indicates that the correct processing of the signal sequence.
  • These examples demonstrate that the protein produced by pVC105 which lacks all of domain I and a portion of domain II was also secreted into the medium when the ompA signal sequence was present.
  • Beta-galactosidase was measured in all experiments and ⁇ 1% of total activity was found in the medium indicating lysis had not occurred.
  • the results of Examples 9 through 13 are presented in Table 3.
  • Examples 14 and 15 illustrate the secretion of chimeric protein TGF-alpha-PE40.
  • a chimeric protein is made by fusing a cDNA encoding TGF-alpha to the 3' end of Pseudomonas exotoxin encoding domains II and III. The resulting protein, PE40-TGF-alpha, accumulated within E. coli and could be purified from extracts of E. coli.
  • a cDNA encoding TGF-alpha is placed at the 5' end of a gene encoding domains II and III to produce a TGF-alpha-PE40 fusion protein. This molecule is about 10-fold more active in killing cells bearing EGF receptors than PE40-TGF-alpha.
  • TGF-alpha-PE40 In the absence of an ompA signal sequence, TGF-alpha-PE40 was found mainly within the cell but about 25% was found in the periplasm and a small but significant amount was found in the medium. The addition of the ompA signal sequence resulted in large amounts of TGF-alpha-PE40 appearing in the medium as well as in the periplasm. The TGF-alpha-PE40 present in the medium and periplasm is slightly smaller than the TGF-alpha-PE40 molecules found within the cell indicating that processing has taken place as shown in Figure 2 G.
  • sequences found within domain II of Pseudomonas exotoxin promote secretion of TGF-alpha-PE40 into the periplasm with some appearing in the medium and the further addition of a signal sequence, such as that of ompA, results in increased secretion of TGF-alpha-PE40 into the medium.
  • a signal sequence such as that of ompA
  • Examples 16 through 23 illustrate that PhoA fusions are secreted.
  • DNA sequences encoding domain II alone or domains II and III were fused to the phoA structural gene which encodes alkaline phosphatase in E. coli.
  • Alkaline phosphatase was chosen because it is secreted into the periplasm only when attached to a signal sequence.
  • ompA signal sequence were included in some of the constructions.
  • the appearance of the fusion proteins into the periplasm and medium was measured in several ways. Aliquots were subjected to PAGE, transferred to nitrocellulose and the proteins located by immunoblotting using an antibody to Pseudomonas exotoxin. In every case the fusion protein had the expected size as shown, for example, in Figure 2H and I.
  • the amount of protein present was estimated from the intensity of the antibody reaction and was confirmed by measurements of ADP-ribosylating or alkaline phosphatase activity. Alkaline phosphatase activity is only exhibited by those proteins secreted out of the cellular interior. E. coli BL21 contains a normal alkaline phosphatase gene that is not expressed because the cells are grown in LB with high phosphate. When alkaline phosphatase was placed at the carboxyl terminus of domains II and II (PE40) or domain II alone as shown in Figure 1D, about 8% of the fusion protein appeared in the medium.
  • Example 24 illustrates the effect of ompA signal sequence in the level of expression. This example compares selected data presented in the other examples described above. An ATG codon was placed in front of various Pseudomonas exotoxin molecules as shown in Figure 1 and Table 1 beginning with the T7 expression plasmid. When the plasmids containing an ompA signal sequence were constructed, a DNA -fragment was used containing both the ompA SD region and signal sequence. This was fused to various Pseudomonas exotoxin molecules . These plasmids consistently made more recombinant protein than those that did not as shown in Tables 2, 3, and 4.
  • ompA has a more efficient SD sequence and (ii) the translation initiation codons in the ompA signal sequence are enriched in A and T and the newly formed RNA can more readily disasssociate from the DNA template and associate with ribosomes.
  • LPP outer membrane lipoprotein

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP19890906964 1988-05-09 1989-05-04 Vector for secretion of proteins directly into periplasm or culture medium Withdrawn EP0422049A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19201388A 1988-05-09 1988-05-09
US192013 1988-05-09

Publications (2)

Publication Number Publication Date
EP0422049A1 true EP0422049A1 (de) 1991-04-17
EP0422049A4 EP0422049A4 (en) 1991-11-13

Family

ID=22707875

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19890906964 Withdrawn EP0422049A4 (en) 1988-05-09 1989-05-04 Vector for secretion of proteins directly into periplasm or culture medium

Country Status (4)

Country Link
EP (1) EP0422049A4 (de)
AU (1) AU3751689A (de)
IL (1) IL90190A0 (de)
WO (1) WO1989010971A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2084992A1 (en) * 1990-06-25 1991-12-26 Osi Pharmaceuticals, Inc. Tissue-derived tumor growth inhibitors, methods for preparation and uses thereof
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5939531A (en) * 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
CA2077277A1 (en) * 1991-09-09 1993-03-10 John J. Donnelly Cellular immunity vaccines from bacterial toxin-antigen conjugates
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
CA2546157C (en) 2003-11-21 2014-07-22 Dow Global Technolgies Inc. Improved expression systems with sec-system secretion
JP2008507294A (ja) 2004-07-26 2008-03-13 ダウ グローバル テクノロジーズ インコーポレイティド 菌株遺伝子操作による改善されたタンパク質発現のための方法
US7579005B2 (en) 2005-11-28 2009-08-25 E. I. Du Pont De Nemours And Company Process for recombinant expression and purification of antimicrobial peptides using periplasmic targeting signals as precipitable hydrophobic tags
EP2468869B1 (de) 2007-01-31 2015-03-18 Pfenex Inc. Bakterielle Leader-Sequenzen für erhöhte Expression
AU2008245696B2 (en) 2007-04-27 2013-11-07 Pelican Technology Holdings, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US8932586B2 (en) 2011-09-06 2015-01-13 Intrexon Corporation Modified forms of Pseudomonas exotoxin A
CN105473154A (zh) 2013-03-12 2016-04-06 通用医疗公司 修饰的缪勒抑制物质(mis)蛋白及其用于疾病治疗的用途
AU2014362307A1 (en) 2013-12-11 2016-06-30 The General Hospital Corporation Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0261671A2 (de) * 1986-09-24 1988-03-30 Ira Pastan Rekombinantes Pseudomonastoxin : Konstruktion eines wirksamen Immunotoxins mit wenigen Nebenwirkungen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0261671A2 (de) * 1986-09-24 1988-03-30 Ira Pastan Rekombinantes Pseudomonastoxin : Konstruktion eines wirksamen Immunotoxins mit wenigen Nebenwirkungen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Biological Chemistry, Vol. 263, No. 19, July 5, 1988, Baltimore US, pages 9470-9475; T. KONDO et al.: "Activity of Immunotoxins constructed with modified Pseudomonas Exotoxin A Lacking the Cell Recognition Domain", page 9471, right column, line 36 - line 48. *
See also references of WO8910971A1 *

Also Published As

Publication number Publication date
IL90190A0 (en) 1989-12-15
EP0422049A4 (en) 1991-11-13
WO1989010971A1 (en) 1989-11-16
AU3751689A (en) 1989-11-29

Similar Documents

Publication Publication Date Title
CA2237296C (en) Process for the preparation of peptides by way of streptavidin fusion proteins
Braun et al. Role of the propeptide in folding and secretion of elastase of Pseudomonas aeruginosa
US5506120A (en) Method of producing peptides or proteins as fusion proteins
Chaudhary et al. Role of domain II of Pseudomonas exotoxin in the secretion of proteins into the periplasm and medium by Escherichia coli.
EP0531404B1 (de) Ubiquitinspezifische protease
US5512459A (en) Enzymatic method for modification or recombinant polypeptides
US5496924A (en) Fusion protein comprising an interleukin-2 fragment ballast portion
EP0422049A1 (de) Vektor zum abscheiden von proteinen direkt in das periplasma oder in das kulturmedium
JP2001061487A (ja) 分子シャペロンの共分泌による自然に折り畳まれた分泌タンパク質の製造法
FR2594846A1 (fr) Procede de preparation de la serum albumine humaine mature
Gray et al. Pseudomonas aeruginosa secretes and correctly processes human growth hormone
EP0797671B1 (de) Verfahren zur herstellung extrazellulärer proteine in bakterien
EP0510018A1 (de) Peptidsignal von lipoprotein verschmolzen mit antigen-polypeptiden
US20110097737A1 (en) Methods and Compositions for Targeting Proteins of Interest to the Host Cell Envelope
KR20020026366A (ko) 단백질의 생산
RU2144957C1 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pPINS07, КОДИРУЮЩАЯ ГИБРИДНЫЙ ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ПРОИНСУЛИН ЧЕЛОВЕКА, И ШТАММ БАКТЕРИЙ Escherichia coli - ПРОДУЦЕНТ ГИБРИДНОГО ПОЛИПЕПТИДА, СОДЕРЖАЩЕГО ПРОИНСУЛИН ЧЕЛОВЕКА
EP0225860B1 (de) Verfahren zur Ausscheidung von Genprodukten in das Wachstumsmedium von gram-negativen Bakterien
KR940010862B1 (ko) 유용한 메탈로프로테이나제 억제제 씨퀀스 재조합 벡터계의 제조를 위한 dna 재조합 방법
Honjo et al. Secretion of human growth hormone in Bacillus subtilis using prepropeptide coding region of Bacillus amyloliquefaciens neutral protease gene
EP0234592A1 (de) Plasmid, das ein DNA-Fragment enthält, welches für die Fc-Region von menschlichem Immunoglobulin G Protein codiert, und Verwendung desselben zur Herstellung des genannten Proteins
US5082775A (en) Efficient process for isolating insoluble heterologous protein using non-ionic detergents
Guzmán‐Verduzco et al. Export and processing analysis of a fusion between the extracellular heat‐stable enterotoxin and the periplasmic B subunit of the heat‐labile enterotoxin in Escherichia coli
KR100714116B1 (ko) 췌장의 프로카복시펩티다제 b를 사용한 인슐린의 제조
JP2637392B2 (ja) 遺伝子操作による生物活性β−NGFの生産方法
Uhland et al. Requirements for translocation of periplasmic domains in polytopic membrane proteins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19901108

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19910925

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19911119